About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
As value-based reimbursement and accountable-care models drive us into an era of cost-containment and care-management strategies, the P&T committee must reinvent itself.
David Shulkin, MD
Health Care & Law
An Improvement Over HMOs?
The ACO model is considered an important achievement of health care reform legislation. However, ACOs might not be able to deliver on their promises in part because of the slowly recovering economy. It is also not clear how much money will be saved, and not all hospitals plan to participate.
Rita M. Marcoux, RPh, MBA; E. Paul Larrat, RPh, PhD; and F. Randy Vogenberg, RPh, PhD
Part 3: Regulatory and Safety Challenges
Before the FDA can set up safety guidelines for nanomedicines, it needs to establish valid testing criteria. The goal is to strike a balance between underregulation (which can lead to questionable approvals) and overregulation (which can inhibit innovation).
C. Lee Ventola, MS
Perspectives in the United States
Twenty percent to 30% of CML patients are not being treated according to clinical practice guidelines. The authors review the most recent guidelines published by the National Comprehensive Cancer Network and the European LeukemiaNet.
David Rizzieri, MD; and Joseph O. Moore, MD
Basal opioid infusions may raise the risk of respiratory depression when given with patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP
Payment Would Be for Transitional Care After Hospital Discharge
A new Medicare ‘G’ code for transitional care may help to reduce the number of hospital readmissions.
FDA approvals, drug indications, and updates
Bosutinib (Bosulif) tablets for chronic myelogenous leukemia; linaclotide (Linzess) for irritable bowel syndrome/constipation and chronic idiopathic constipation; and regorafenib (Stivarga) tablets for metastatic colorectal cancer
Marvin M. Goldenberg, PhD, RPh, MS